BRPI0510367A - methods and compositions for the treatment of polycystic diseases - Google Patents

methods and compositions for the treatment of polycystic diseases

Info

Publication number
BRPI0510367A
BRPI0510367A BRPI0510367-3A BRPI0510367A BRPI0510367A BR PI0510367 A BRPI0510367 A BR PI0510367A BR PI0510367 A BRPI0510367 A BR PI0510367A BR PI0510367 A BRPI0510367 A BR PI0510367A
Authority
BR
Brazil
Prior art keywords
methods
compositions
gene
treatment
diseases
Prior art date
Application number
BRPI0510367-3A
Other languages
Portuguese (pt)
Inventor
Oxana Beskrovnaya
Herve Husson
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of BRPI0510367A publication Critical patent/BRPI0510367A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

MéTODOS E COMPOSIçõES PARA O TRATAMENTO DE DOENçAS POLICìSTICAS. A presente invenção refere-se a composições e métodos para diagnosticar e tratar distúrbios policísticos através da inibição da atividade biológica de um gene agora relacionado com o aparecimento desse distúrbio. Somente a título de ilustração, o gene do Fator de Crescimento do Tecido Conectivo (CTGF) é um exemplo de tal gene. Também são providos por esta invenção composições e métodos para tratar ou aliviar lesões císticas anormais e doenças associadas com a formação de cistos no tecido. Os métodos e as composições tratam e aliviam a formação patológica de cistos nos tecidos através da inibição ou do aumento da expressão do gene, ou da atividade biológica do seu produto da sua expressão do gene ou do seu receptor.METHODS AND COMPOSITIONS FOR TREATMENT OF POLITICALLY DISEASES. The present invention relates to compositions and methods for diagnosing and treating polycystic disorders by inhibiting the biological activity of a gene now related to the onset of such disorder. By way of illustration only, the Connective Tissue Growth Factor (CTGF) gene is an example of such a gene. Also provided by this invention are compositions and methods for treating or alleviating abnormal cystic lesions and diseases associated with tissue cyst formation. The methods and compositions treat and alleviate pathological formation of cysts in tissues by inhibiting or increasing gene expression, or biological activity of their product from gene expression or receptor expression.

BRPI0510367-3A 2004-04-29 2005-04-29 methods and compositions for the treatment of polycystic diseases BRPI0510367A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56667004P 2004-04-29 2004-04-29
US59038504P 2004-07-22 2004-07-22
PCT/US2005/014982 WO2005117941A2 (en) 2004-04-29 2005-04-29 Methods and compositions for the treatment of polycystic diseases

Publications (1)

Publication Number Publication Date
BRPI0510367A true BRPI0510367A (en) 2007-11-06

Family

ID=35463346

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510367-3A BRPI0510367A (en) 2004-04-29 2005-04-29 methods and compositions for the treatment of polycystic diseases

Country Status (6)

Country Link
EP (1) EP1740221A4 (en)
JP (1) JP2007535562A (en)
BR (1) BRPI0510367A (en)
CA (1) CA2564092A1 (en)
MX (1) MXPA06012446A (en)
WO (1) WO2005117941A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG177194A1 (en) 2005-12-08 2012-01-30 Medarex Inc Human monoclonal antibodies to protein tyrosine kinase 7 (ptk7) and methods for using anti-ptk7 antibodies
EP1808694A1 (en) * 2006-01-17 2007-07-18 Universitätsklinikum Freiburg Method for diagnosing polycystic kidney disease
DK2076268T3 (en) * 2006-10-19 2013-04-22 Genzyme Corp Roscovitine for the treatment of certain cystic diseases
NZ591416A (en) 2008-08-25 2012-11-30 Excaliard Pharmaceuticals Inc Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
US8946172B2 (en) 2008-08-25 2015-02-03 Excaliard Pharmaceuticals, Inc. Method for reducing scarring during wound healing using antisense compounds directed to CTGF
PL2670411T3 (en) 2011-02-02 2019-09-30 Excaliard Pharmaceuticals, Inc. Antisense compounds targeting connective tissue growth factor (ctgf) for use in a method of treating keloids or hypertrophic scars
JP5995207B2 (en) * 2014-11-28 2016-09-21 学校法人 学習院 Boron-containing porphyrin derivatives
KR102288447B1 (en) * 2018-12-28 2021-08-10 서울대학교산학협력단 Composition for diagnosing polycystic kidney disease comprising agent for detecting CTGF and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789189A (en) * 1993-09-24 1998-08-04 The Regents Of The University Of California Inhibition of cyst formation by cytoskeletal specific drugs
US6562618B1 (en) * 1997-12-25 2003-05-13 Japan Tobacco, Inc. Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
US6875747B1 (en) * 1999-05-24 2005-04-05 Avi Bio Pharma, Inc. Antisense to c-myc for treatment of polycystic kidney disease
US20030113816A1 (en) * 2001-09-18 2003-06-19 Weitz Stephen L. Methods of assaying connective tissue growth factor
US6965025B2 (en) * 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression

Also Published As

Publication number Publication date
EP1740221A4 (en) 2009-01-07
EP1740221A2 (en) 2007-01-10
WO2005117941A2 (en) 2005-12-15
WO2005117941A3 (en) 2006-05-18
MXPA06012446A (en) 2007-01-17
JP2007535562A (en) 2007-12-06
CA2564092A1 (en) 2005-12-15

Similar Documents

Publication Publication Date Title
BRPI0510367A (en) methods and compositions for the treatment of polycystic diseases
Mendes et al. Lithium reduces Gsk3b mRNA levels: implications for Alzheimer disease
Zhang et al. Endoplasmic reticulum stress: relevance and therapeutics in central nervous system diseases
MX2021009178A (en) Oligonucleotide compositions and methods thereof.
Muneer et al. Endoplasmic reticulum stress: implications for neuropsychiatric disorders
WO2004065576A3 (en) Methods and compositions for the treatment of urological disorder using differential expressed polypeptides
BRPI0306973B8 (en) anti-igf-ir antibodies, their production method and their uses, murine hybridoma, isolated nucleic acid, vector, composition, kit or kit, and in vitro diagnostic method of diseases induced by an overexpression or underexpression of the igf-ir receptor
JP7212781B2 (en) Inhibitors of SARM1 in combination with neuroprotective agents
WO2009011871A3 (en) Thiadiazole modulators of pkb
Ni et al. Long-term effects of recurrent neonatal seizures on neurobehavioral function and related gene expression and its intervention by inhibitor of cathepsin B
WO2007046087A3 (en) Pharmaceutical compositions and diagnostic methods for inflammatory skin disesaes, disorders or conditions
Lu et al. Isoquercetin ameliorates tunicamycin-induced apoptosis in rat dorsal root ganglion neurons via suppressing ROS-dependent endoplasmic reticulum stress
BRPI0512496A (en) processes and compositions for the treatment of polycystic diseases
Smeele et al. Snapshots from within the cell: Novel trafficking and non trafficking functions of Snap29 during tissue morphogenesis
Xu et al. Neuroprotective effects of ebselen are associated with the regulation of Bcl-2 and Bax proteins in cultured mouse cortical neurons
Baek et al. Insulin withdrawal-induced cell death in adult hippocampal neural stem cells as a model of autophagic cell death
Wu et al. PKC isozymes in the enhanced regrowth of retinal neurites after optic nerve injury
WO2003073983A3 (en) Methods and compositions in treating pain using diacylglycerol kinase epsilon
Li et al. Valproic acid protects neurons and promotes neuronal regeneration after brachial plexus avulsion
WO2003030836A3 (en) Neuronal regeneration
Nakayama et al. A gain-of-function screen to identify genes that reduce lifespan in the adult of Drosophila melanogaster
Bossy et al. Clearing the brain's cobwebs: the role of autophagy in neuroprotection
Robert Tumors perturbing extracellular matrix biosynthesis. The case of von Recklinghausen's disease
De la Rosa et al. CNS Targets for the Treatment of Retinal Dystrophies: A Win–Win Strategy
Gould et al. Sarm1 Haploinsufficiency and Low Expression Levels after Antisense Oligonucleotides Delays Programmed Axon Degeneration

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.